Straits Times Index
3,313.35 +9.69 (+0.29%) S&P 500
5,229.15 +7.73 (+0.15%) Dow
39,451.85 +20.34 (+0.05%) Nasdaq
16,455.59 +67.35 (+0.41%) Bitcoin USD
61,885.55 -1,101.96 (-1.75%) CMC Crypto 200
1,271.83 -19.56 (-1.51%)
NVO Jul 2024 140.000 put
- Zacks
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- Reuters
UPDATE 3-Wegovy users keep weight off for four years, Novo Nordisk study says
Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker's case to insurers and governments to cover the cost of the effective but expensive drug. The Danish drugmaker presented the new long-term data on Tuesday at the European Congress on Obesity in Venice, Italy, in a new analysis from a large study for which substantial results had been published last year. "This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo's head of development, said in an interview, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic.
- Reuters
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo presented the new long-term data at the European Congress on Obesity in Venice, Italy, gleaned from a large study for which much of the results had been published last year. "This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo's head of development, said in an interview, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic.
